Kim A. Connelly

FRACP, PhD, MBBS

Scientist

Biography

Dr. Kim Connelly is a Cardiologist and Scientist who is both nationally recognized as an expert in echocardiography, cardiovascular MRI and the impact of diabetes upon cardiac function and ventricular remodeling. His work has been recognized evident by winning the “Young Investigator of the Year Award” by the Canadian Cardiovascular Society, an Early Researcher Award in 2014, and a CIHR New Investigator award in 2014.

Dr. Connelly runs a basic research laboratory at the Keenan Research Centre at St. Michael’s Hospital where he focuses upon basic mechanisms of disease – primarily around the role of pathological extracellular matrix accumulation and the pro-sclerotic cytokine transforming growth factor beta, with a focus upon translating discoveries into therapies in humans. He developed the first hemodynamically validated model of diabetes induced HFpEF. He is the Director of the Krembil Stem Cell Facility at St. Michael’s Hospital and uses regenerative cell based therapies to improve cardiac and renal dysfunction as a result of diabetes. He has research support from the HSF of Canada, CIHR and CFI along with significant research support from the pharmaceutical industry. His work has been published in journals such as the NEJM, Circulation, Journal of the American college of Cardiology, Circulation Research, Diabetes, Cell Metabolism and Lancet Endocrinology and Diabetes.

His H index is 45, and I index of 140.

Dr Connelly is immediate past president of the Canadian Society of Cardiac Magnetic resonance imaging. He runs a translational imaging laboratory and uses hyperpolarized C13 metabolic imaging to understand metabolism in the human heart in real time, as well as CMR to understand the impact of exercise upon cardiac remodeling. He was senior author of the EMPA HEART study along with Dr Verma and Zinman to assess the mechanism by which the SGLT2i empagliflozin provided cardiac protection in patients with type 2 DM. Finally, he was past section lead of 2018 macrovascular complications section for the Diabetes Canada Clinical practice updates and is current chair of the Canadian Cardiovascular Society guidelines.

Recent Publications

  1. Ali, MU, Mancini, GBJ, Fitzpatrick-Lewis, D, Lewis, R, Jovkovic, M, Zieroth, S et al.. The Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists on Cardiorenal Outcomes: Systematic Review and Meta-analysis. Can J Cardiol. 2022;38 (8):1201-1210. doi: 10.1016/j.cjca.2022.05.011. PubMed PMID:35961756 .
  2. Mancini, GBJ, O'Meara, E, Zieroth, S, Bernier, M, Cheng, AYY, Cherney, DZI et al.. 2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults. Can J Cardiol. 2022;38 (8):1153-1167. doi: 10.1016/j.cjca.2022.04.029. PubMed PMID:35961754 .
  3. Hibino, M, Pandey, AK, Chan, V, Mazer, CD, Rumman, R, Dhingra, NK et al.. Risk Factors for Postrepair Elevated Mitral Gradient: A Post-hoc Analysis of a Randomized Trial. Ann Thorac Surg. 2022; :. doi: 10.1016/j.athoracsur.2022.05.053. PubMed PMID:35779599 .
  4. Hibino, M, Dhingra, NK, Chan, V, Mazer, CD, Teoh, H, Quan, A et al.. Stage-based approach to predict left ventricular reverse remodeling after mitral repair. Clin Cardiol. 2022; :. doi: 10.1002/clc.23879. PubMed PMID:35748086 .
  5. Vervoort, D, An, KR, Elbatarny, M, Tam, DY, Quastel, A, Verma, S et al.. Dealing With the Epidemic of Endocarditis in People Who Inject Drugs. Can J Cardiol. 2022; :. doi: 10.1016/j.cjca.2022.06.004. PubMed PMID:35691567 .
  6. Sharma, A, Verma, S, Bhatt, DL, Connelly, KA, Swiggum, E, Vaduganathan, M et al.. Optimizing Foundational Therapies in Patients With HFrEF: How Do We Translate These Findings Into Clinical Care?. JACC Basic Transl Sci. 2022;7 (5):504-517. doi: 10.1016/j.jacbts.2021.10.018. PubMed PMID:35663626 PubMed Central PMC9156437.
  7. Moulson, N, Connelly, KA, Dorian, P, Fournier, A, Goodman, JM, Grubic, N et al.. COVID-19, Inflammatory Heart Disease, and Vaccination in the Athlete and Highly Active Person: An Update and Further Considerations. Can J Cardiol. 2022; :. doi: 10.1016/j.cjca.2022.05.019. PubMed PMID:35643383 PubMed Central PMC9132493.
  8. Connelly, KA, Sarak, B. Diabetes and Myocardial Fibrosis: Is CMR the Force Leading to the Rise of "Scar Wars"?. JACC Cardiovasc Imaging. 2022;15 (5):809-811. doi: 10.1016/j.jcmg.2022.01.015. PubMed PMID:35512953 .
  9. Rathi, A, Kanee, L, Limoges, M, Connelly, KA, Jimenez Juan, L, Kirpalani, A et al.. Relationship Between Left Ventricular Strain Assessment by Cardiac Magnetic Resonance Imaging and Response to Cardiac Resynchronization Therapy. J Thorac Imaging. 2022;37 (4):W58-W59. doi: 10.1097/RTI.0000000000000652. PubMed PMID:35438668 .
  10. Veitch, S, Njock, MS, Chandy, M, Siraj, MA, Chi, L, Mak, H et al.. MiR-30 promotes fatty acid beta-oxidation and endothelial cell dysfunction and is a circulating biomarker of coronary microvascular dysfunction in pre-clinical models of diabetes. Cardiovasc Diabetol. 2022;21 (1):31. doi: 10.1186/s12933-022-01458-z. PubMed PMID:35209901 PubMed Central PMC8876371.
Search PubMed

Affiliations & Other Activities

  • Director, Krembil Stem Cell Facility, St. Michael’s Hospital
  • Staff Cardiologist, Division of Cardiology, St. Michael’s Hospital
  • Member, Richard Lewar Center, University of Toronto
  • Cardiologist, Division of Cardiology, Sunnybrook Health Sciences Centre